The primary new stimulus from retatrutide is the glucagon receptor activation
Some individuals experience nausea or other gastrointestinal effects during initial adjustment
Mouhammad ZA, Vohra R, Horwitz A, Thein AS, Rovelt J, Cvenkel B, Williams PA, Azuara-Blanco A, Kolko M (2022) Glucagon-Like Peptide 1 Receptor Agonists -Potential Game Changers in the Treatment of Glaucoma
Have tried losing weight through other ways first, including diet, exercise, and medication
Although these findings offer reassurance regarding the safety of these drugs, further validation is essential
Most private providers follow criteria broadly aligned with NICE guidance: A BMI of 30 or above , or A BMI of 37 or above alongside a weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea Some providers may consider patients with a BMI slightly below these thresholds at clinical discretion